Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0NJ5H
|
||||
| Former ID |
DCL000421
|
||||
| Drug Name |
Alogliptin
|
||||
| Synonyms |
UNII-JHC049LO86; 2-({6-[(3r)-3-Aminopiperidin-1-Yl]-3-Methyl-2,4-Dioxo-3,4-Dihydropyrimidin-1(2h)-Yl}methyl)benzonitrile; 850649-61-5
|
||||
| Drug Type |
Small molecular drug
|
||||
| Company |
Takeda
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C18H21N5O2
|
||||
| InChI |
InChI=1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1
|
||||
| InChIKey |
ZSBOMTDTBDDKMP-OAHLLOKOSA-N
|
||||
| CAS Number |
CAS 850649-61-5
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
16549582, 23591487, 42529629, 46516529, 57376680, 79634689, 87544227, 93300285, 103516453, 126665588, 134339050, 135207592, 137147468, 140812881, 160962873, 162009811, 162253849, 164193948, 164835224, 175265639, 175427056, 178102937, 185988964, 210279140, 210281462, 223574691, 223683116, 224085697, 226492557, 241154940, 244648029, 249810610, 251971115, 252214702, 252553765, 252671739
|
||||
| Target and Pathway | |||||
| Target(s) | Dipeptidyl peptidase IV | Target Info | Inhibitor | [537022], [537230], [551717] | |
| KEGG Pathway | Protein digestion and absorption | ||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | |||||
| References | |||||
| Ref 532651 | 2013 FDA drug approvals. Nat Rev Drug Discov. 2014 Feb;13(2):85-9. | ||||
| Ref 541465 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6319). | ||||
| Ref 537022 | Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87. | ||||
| Ref 537230 | Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice. Br J Pharmacol. 2009 Jun;157(3):415-26. Epub 2009 Apr 3. | ||||
| Ref 551717 | Clinical pipeline report, company report or official report of Takeda (2009). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.